Pfizer Stock Slips After Report on Vaccine Timing Probe
Pfizer stock slipped about 0.7% to $25.19 after The Wall Street Journal reported on an inquiry looking into the suggestion that the pharmaceutical giant delayed announcing a successful vaccine against Covid-19 until after the election that Trump lost to Biden.
Here are three reasons why Pfizer could prove to be a steal of a deal this year. Buying quality stocks at decent valuations ...
Additionally, US exchanges like the New York Stock Exchange and Nasdaq are among the ... Number of Hedge Fund Holders: 80 Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets ...
Equities research analysts at Zacks Research reduced their Q2 2026 earnings per share (EPS) estimates for Pfizer in a report issued on Thursday, March 20th. Zacks Research analyst K. Shah now ...
In this article, we are going to take a look at where Pfizer Inc. (NYSE ... appeared on CNBC’s ‘The Exchange’ and began discussing his fund’s performance. Despite a challenging market ...
Pfizer stock has delivered its long-term shareholders a dividend that has grown for 16 consecutive years. The pace of those ...
With Pfizer’s final stake sale in the bag, the two Big Pharma companies behind Haleon’s genesis have formally parted ways with the standalone consumer health giant. | After charting similar moves ...
Community Bank N.A. cut its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 26.5% in the fourth quarter, according to its ...
Pfizer (PFE) stock in focus as the company sells its entire 7.3% stake in Haleon (HLN) for $3.24B. Read more here.
senior market strategist for the New York Stock Exchange. Sign up for Kiplinger's FREE Investing Weekly e-letter for stock, ETF and mutual fund recommendations, and other investing advice.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback